Table 1.
Baseline characteristics (mean ± SD) n (%)
| Group A calcium/vitamin D | Group B0/1 + sodium fluoride | Group C0/1 + ibandronate | |
| No. of patients | 32 | 62 | 54 |
| Male/female | 14/18 | 29/33 | 27/27 |
| Age (yr) | 33.8 ± 9.76 | 35.7 ± 12.8 | 36.8 ± 13.1 |
| Duration of disease (yr) | 7.4 ± 1.7 | 9.4 ± 2.1 | 8.1 ± 1.9 |
| Smoking | 13 (40.6) | 23 (37.1) | 19 (35.2) |
| Postmenopausal | 0 | 2 | 1 |
| Extent of disease | |||
| Ileal disease | 11 (34.4) | 20 (32.3) | 21 (38.9) |
| Colonic disease | 5 (15.6) | 8 (12.9) | 7 (13) |
| Ileocolonic disease | 16 (50.0) | 34 (54.8) | 26 (48.1) |
| Bowel resection | |||
| No bowel resection | 18 (56.2) | 39 (62.9) | 29 (53.7) |
| Ileal resection | 8 (25.0) | 12 (19.4) | 14 (25.9) |
| Colonic resection | 2 (6.2) | 5 (8.1) | 4 (7.4) |
| Ileocolonic resection | 4 (12.6) | 6 (9.7) | 7 (13) |
| Patients with bowel resection during study | 4 | 6 | 5 |
| Use of corticosteroids | |||
| No previous use | 3 (9.4) | 6 (9.7) | 6 (11.1) |
| Cumulative dose < 10 g | 22 (68.8) | 36 (58.1) | 34 (63) |
| Cumulative dose > 10 g | 7 (21.8) | 28 (32.2) | 14 (25.9) |
| Body weight (kg) | 69.4 ± 15.51 | 63.71 ± 11.9 | 64.8 ± 13.91 |
| Body height (cm) | 172 ± 7.63 | 170 ± 8.8 | 170 ± 9.0 |
| BMI (kg/m2) | 23.54 ± 5.34 | 22.01 ± 3.6 | 22. 4 ± 3.92 |
| CDAI | 141.5 ± 100.96 | 145 ± 95.5 | 135.9 ± 85.03 |
| T-score spine | -1.57 ± 0.31 | -1.82 ± 0.75 | -1.89 ± 0.71 |
| BMD spine (g/cm2) | 0.90 ± 0.04 | 0.87 ± 0.09 | 0.85 ± 0.08 |
| Pre-existing vertebral fractures1 | 6 (22.2) of patients with 10 fractures | 9 (19.2) of patients with 18 fractures | 14 (28.6) of patients with 28 fractures |
1
Intention to treat (ITT) analysis. BMI: Body mass index; CDAI: Crohn’s disease activity index; BMD: Bone mineral density.